With $1 billion in facility-specific investment and 370 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Amgen (Holly Springs Expansion)
- Industry
- Pharmaceuticals
- Location
- Holly Springs, North Carolina
- Investment
- $1.00B
- Permanent jobs announced
- 370
- Status
- Under Construction
- Announced
- Dec 5, 2024
- Expected opening
- Jan 1, 2027
- Added to tracker
- Feb 25, 2026
Official references
- Amgen's December 5, 2024 $1 billion North Carolina expansion announcement https://www.amgen.com/newsroom/press-releases/2024/12/amgen-announces-$1-billion-manufacturing-expansion-in-north-carolina
Other projects to know
- PharmaceuticalsAbbVieDurham, North Carolina$1.40B734 jobs
- PharmaceuticalsJohnson & Johnson (Innovative Medicine)Wilson, North CarolinaNot publicly disclosed500 jobs
- PharmaceuticalsRoche Group (Genentech)Holly Springs, North Carolina$2.00B500 jobs
- PharmaceuticalsJohnson & JohnsonWilson, North Carolina$2.00B420 jobs